NMs | Size | Cells/animals | Dose and exposure time | Effects | References |
---|---|---|---|---|---|
Si-NPs | 64.43 ± 10.50 nm | ICR mice | 20 mg/kg b.w., 15 d, intravenous injection | Induced hepatic damage, fibrosis, and TGF-β1/SMAD3 signaling activation | [6] |
TiO2-NPs | 21Â nm | Rats | 0.5, 1.5, 5, 15, 50, and 150Â mg/kg b.w.; intratracheal instillation, 1Â month | Induced hepatic profibrotic alterations | [57] |
TiO2-NPs | 5–6 nm | ICR mice | 2.5, 5, and 10 mg/kg b.w.; oral administration, 9 months | Triggered hepatic fibrosis and upregulated expression of TGF-β/SMAD/MAPK/WNT pathway-related factors | [58] |
Cu-NPs | 32.7 ± 10.45 nm | SD rats | 100, 200, or 400 mg/kg b.w./day; 28 d, oral administration, | Induced early hepatic fibrotic changes via TGF-β/SMAD signaling | [60] |
Ag-NPs | 56Â nm | SD rats | 30, 125, 500Â mg/kg b.w., oral exposure, 13 w | Triggered fibrosis in the bile duct | [63] |
TiO2-NPs | 6.5 nm | ICR mice | 2.5, 5, 10 mg/kg b.w.; nasal exposure, 9 months | Induced pulmonary toxicity involving reactive free radical-activated TGF-β/SMAD/P38MAPK/WNT signaling | [66] |
NiO-NPs | 44 nm | Wistar rats, HepG2 cells | 0.015–0.24 mg/kg, 9 w, intratracheal instillation | Induced elevated levels of types I and III collagen in the liver and proteins involved in TGF-β1-mediated SMAD pathway | [64] |
MWCNTs, SWCNTs, Carbon black | CNTs: 0.3–49 nm × 0.5–10 μm, Silica: 1.6 μm Black carbon: 14 nm | J774A macrophages | 2.5 μg/mL, 24 h | MWCNTs and SWCNTs stimulated myofibroblast transformation of macrophages | [201] |